Under his directorship, the Respiratory Research Division has attracted national and international funding, including grants from the Health Research Board, Science Foundation Ireland, the Higher Education Authority, the CF Association of Ireland, and the US Alpha-1 Foundation. In 1999, Beaumont Hospital was the first site worldwide for intravenous administration of transgenic alpha 1-antitrypsin to individuals with alpha-1 antitrypsin deficiency. 2004 saw the first phase 1 study in Beaumont Hospital of Lomucin, a medication developed to block abnormal mucin production from bronchial epithelium. This work arose directly from research carried out in the Respiratory Research Division.
In 2001, Professor McElvaney founded the Alpha One Foundation of Ireland. Subsequently, he received funding from the Department of Health and Children to establish the first targeted detection programme for alpha-1 antitrypsin deficiency in Europe. This genetic condition is associated with risk for lung, liver, and skin problems, and Professor McElvaney has been carrying out research into AATD for over 20 years.
His research priorities include protease/antiprotease interactions in the lung; signal transduction in bronchial epithelium; innate defences of the lung; and gene therapy for lung diseases.
There are 670 publications listed in Google Scholar. His hindex is 66, i10 is 179, and total citations are 14,485. A search on Pubmed reveals 215 listings as of January 2018. He has recently completed a first-in-man trial on a novel cytoprotective agent for acute myocardial infarction in patients with poor systolic function post-infarction. He serves on the advisory board of a number of the world's leading multinational pharmaceutical and biotechnology companies and as a scientific consultant in the fields of vascular biology, experimental animal models, cardiac cytoprotection post-myocardial infarction, and vascular stem cell biology.
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He has published over 160 papers in the scientific literature as manuscripts and conference papers and his work has been cited > 5800 times with an h-index > 40. References His indices on Google Scholar are h-index 58 and I10-index 120 with citation number 18,822.
